Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)

NCT02230761 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Lower Eyelid Steatoblepharon (Excess Eyelid Fat)

Interventions

DRUG: XOPH5 Ointment
DRUG: Placebo

Sponsor

Topokine Therapeutics, Inc.